Astec LifeSciences growth ratios

·ChemicalsChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+17.5%−16.8%−27.1%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+93.2%−1,019.8%−107.8%
+55.0%−160.7%−199.0%
+40.0%−187.3%−283.2%
+45.0%−187.1%−283.5%
+6.9%−9.6%−0.5%
+66.3%−36.4%−11.9%
−861.0%−182.2%−86.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ASTEC₹661.00

Astec LifeSciences Limited

· Chemicals
₹ CrorePeersPUNJABCHEMMOLIPLINSECTICIDDHARMAJBHARATRASADVANCEHERANBAMcap ₹1,473 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—-27.1-16.8+17.5—
EBITDA Growth—-107.8-1,019.8+93.2—
EBIT Growth—-199.0-160.7+55.0—
Net Income Growth—-283.2-187.3+40.0—
EPS Growth—-283.5-187.1+45.0—
Total Assets Growth—-0.5-9.6+6.9—
Total Equity Growth—-11.9-36.4+66.3—
Cash from Operations Growth—-86.3-182.2-861.0—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.